InfraScan

Executive Summary

InfraScan is a US-based private medical device company specializing in point-of-care diagnostics for traumatic brain injury (TBI). Its flagship product, the Infrascanner, is a handheld, non-invasive device that uses near-infrared spectroscopy (NIRS) to rapidly detect intracranial hematomas. Designed for use in pre-hospital, military, and sports settings, the Infrascanner addresses a critical need for timely TBI assessment, where every minute counts. The company was founded in 2005 and is headquartered in Philadelphia. Despite being in operation for nearly two decades, InfraScan remains relatively under the radar, with limited public information on funding rounds or revenue. However, its technology has significant potential to improve outcomes in emergency medicine and reduce unnecessary CT scans. The global market for TBI diagnostics is substantial, driven by rising incidence of head injuries from accidents, sports, and military conflicts. InfraScan's NIRS-based approach offers a portable, low-cost alternative to CT imaging, making it suitable for field use and resource-limited settings. With growing awareness of concussion management and regulatory pathways for novel neurological diagnostics, InfraScan may be poised for growth. Key near-term catalysts include potential FDA clearance for expanded indications or next-generation device, results from pivotal clinical trials, and strategic partnerships with trauma centers or military organizations. The company's ability to scale manufacturing and commercialize effectively will determine its success. Overall, InfraScan represents a compelling opportunity in the underserved TBI diagnostics space, though validation of clinical and commercial traction is needed.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance for Expanded Indication (e.g., pediatric use or battlefield deployment)60% success
• Q2 2027Publication of Pivotal Clinical Trial Results Demonstrating Diagnostic Accuracy70% success
• Q3 2026Strategic Partnership or Acquisition by Larger MedTech or Military Contractor50% success